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Open access under CC BY-NAdjuvant therapy employing cytotoxic chemotherapy, molecularly targeted agents, immunologic, and
hormonal agents has shown a signiﬁcant impact upon a variety of solid tumors. The principles that guide
adjuvant therapy differ among various tumor types and speciﬁc modalities, but generally indicate a
greater impact of therapy in the postsurgical setting of micrometastatic disease, for which adjuvant ther-
apy is commonly pursued, vs. the setting of gross unresectable disease. This review of adjuvant therapies
in current use for ﬁve major solid tumors highlights the rationale for current effective adjuvant therapy,
and draws comparisons between the adjuvant regimens that have found application in solid tumors.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
The aim of systemic adjuvant therapy following tumor resec-
tion is to reduce the risk of disease recurrence and distant metas-
tasis, thereby improving survival. Recurrence risks after resection
generally increase with the extent of invasion of primary tumor
and degree of regional lymph node involvement. In solid tumors,
adjuvant therapy ranges from chemotherapy that has shown ben-
eﬁt in advanced disease to more speciﬁc application of hormonal,+1 412 623 7704.
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C-ND license.                  immune, and molecularly targeted therapies. Adjuvant use of
these agents is based upon increased understanding of tumor
biology and progression pathways, as well as an understanding
of the processes that accompany progression (e.g., immunomodu-
lation). In colon cancer, recent trials suggest that we cannot
always extrapolate outcomes in advanced disease to the adjuvant
setting, particularly with targeted therapies, and that new para-
digms are needed to identify agents that should be considered
for use in the adjuvant setting. This overview of the current status
of adjuvant therapy for a number of paradigmatic solid tumors
compares and contrasts the progress that has been made in the
different disease areas. Non-small-cell lung cancer (NSCLC), colo-
rectal cancer, sarcoma, melanoma, and breast cancer were
selected for this review as leading solid tumors that represent
the major incident and rising tumors, as well as tumors for which
the use of adjuvant therapy has been established in cooperative
group studies. Information sources searched were online libraries
(PubMed/Medline) and recognized national/international treat-
ment guidelines.
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The current adjuvant therapies applicable for the major solid
tumors reviewed here are summarized in Table 1.
In non-small-cell lung cancer (NSCLC), adjuvant chemotherapy
is currently considered following resection of stage II–III disease
and in high-risk, margin-negative, stage IB disease (Table 1).1 Cis-
platin-based chemotherapy doublets are the mainstay of adjuvant
therapy. Various doses and regimens are used but commonly 4 cy-
cles of 21 or 28 days are given. There is no speciﬁc recommenda-
tion to treat based on histologic subtype. However, in the
treatment of metastatic NSCLC, a subgroup analysis of squamous
cell histology demonstrated inferior survival in the cisplatin and
pemetrexed arm.2 It is unclear if this can be extrapolated to the
adjuvant setting.
Chemotherapy based on 5-ﬂuorouracil (5FU) is the standard
adjuvant therapy for resected stage III colorectal cancer; its relative
contribution in stage II disease remains controversial. National
Comprehensive Cancer Network (NCCN) guidelines3 recommend
6 months of adjuvant chemotherapy with combinations of 5FU/
leucovorin [LV]/oxaliplatin (FOLFOX; FLOX), capecitabine/oxalipla-
tin (XELOX; CapeOx), capecitabine alone, or 5FU/LV alone, in stage
III disease and in high/intermediate-risk stage II patients, based on
clinicopathologic risk factors after discussion of the risks and ben-
eﬁts with the patient (Table 1). If oxaliplatin is not appropriate,
5FU/LV may be used. Observation, 5FU/LV, capecitabine, or a clin-
ical trial is recommended for stage II disease without high-risk
features.Table 1
Current adjuvant systemic therapy for ﬁve major solid tumors.
Tumor Adjuvant therapy
NSCLC1 Cisplatin-based chemotherapy doubletsa
Carboplatin and paclitaxel
Colon cancer3 FOLFOX or FLOX or XELOX (CapeOx)
5FU/LV
Capecitabine alone
Observation, 5FU/LV, capecitabine, or clinical trial
Osteosarcoma4 Cisplatin and doxorubicin ± high dose methotrexate ± ifosfamide
Ifosfamide + etoposide (IE)
Ifosfamide + cisplatin + epirubicin
Ewing’s
sarcoma4
Vincristine, doxorubicin, cyclophosphamide, ifosfamide and
etoposide combination
Soft tissue
sarcoma8
Doxorubicin-based CTe
Epirubicin and ifosfamide
Melanoma IFN-a (high and intermediate dose) or
PEG-IFN-a2b
Breast
cancer15,18
Endocrine therapy
(tamoxifen, aromatase inhibitors)
Anti-HER2 therapy
Chemotherapy (doublets or triplets)f
Anthracycline/cyclophosphamide doublet with sequential taxane
ER, estrogen receptor; FLOX/FOLFOX, 5FU/LV/oxaliplatin; HER2, human epidermal gro
oxaliplatin.
a Cisplatin plus vinorelbine or etoposide or vinblastine or gemcitabine or docetaxel.
b Estimates based on SEER Cancer Statistics Review (1975–2008) data for localized an
would not be suitable for adjuvant therapy).
c T4 tumors (IIB or IIC), grade 3 or 4, lymphovascular or perineural invasion, bowel obst
sampled nodes.
d Estimated from the American Joint Committee on Cancer 7th edition (page 154).
e Combination agents include ifosfamide, dacarbazine and mesna.
f Examples of commonly used doublets include TC (docataxel, cyclophosphamide) and
methotrexate, and 5FU), FEC (5FU, epirubin, cyclophosphamide), and TAC (docetaxel, doSarcomas are a biologically complex group of mesenchymal tu-
mors. Chemotherapy using anthracyclines and alkylating agents is
currently the standard adjuvant approach for osteosarcoma,
Ewing’s sarcoma, and soft tissue sarcomas (STS). Adjuvant chemo-
therapy is accepted for the treatment of localized, high-grade oste-
osarcoma and is recommended in low grade or periosteal sarcoma
with high-grade pathology.4 The currently recommended combi-
nation chemotherapy regimens are summarized in Table 1. In Ew-
ing’s sarcoma, the high rates of relapse after local therapy suggest
that micrometastatic disease should be considered present at diag-
nosis.5–7 Therefore, adjuvant therapy with cyclophosphamide,
doxorubicin, vincristine, ifosfamide and etoposide combinations
is recommended in all patients (Table 1).4 In STS, adjuvant chemo-
therapy has resulted in small but consistent beneﬁts. Adjuvant
doxorubicin in combination with other chemotherapy agents is
accepted (Table 1). NCCN guidelines suggest anthracycline-based
adjuvant chemotherapy in high-risk patients with good perfor-
mance status.8 However, the use of adjuvant chemotherapy in
STS remains controversial and is therefore subject to regional and
individual practice patterns; patient selection is paramount. It
should be restricted to patients with high-risk stage II and III dis-
ease at presentation, identiﬁed on the basis of clinicopathologic
features, namely those with large (>5 cm), high-grade extremity
tumors, excellent performance status, and no comorbidities that
would increase their risk of cardiac and/or renal failure associated
with doxorubicin and ifosfamide. For truncal or retroperitoneal
sarcomas the evidence is less supportive, and treatment should
be considered on a case-by-case basis.Selection factor Proportion of
patients eligible
High-risk margin-negative stage IB
Stage II-III
<37%b
Patients as above not able to tolerate cisplatin –
High or intermediate risk stage IIc
Stage III
21%d
As above if oxaliplatin not appropriate –
Stage II without high-risk features -
High-grade disease
Low-grade disease with high-grade pathology
>90%
All patients 100%
Stage II–III 50–60%
Stage IIB–III
Stage IIIA/N1
<92%b
Stage I–III disease
ER and/or PR-positive disease
60–70%
Stage I-III disease
HER2/neu overexpressing disease
15–20%
Stage I–III
Selection based upon recurrence risk, age,
comorbidities, and other factors
60–70%
wth factor receptor 2; PR, progesterone receptor; XELOX (CapeOx), capecitabine/
d regional disease at diagnosis (includes patients with very early stage disease who
ruction, localized perforation or close/indeterminate/positive margins, inadequately
AC (doxorubicin, cyclophosphamide), and triplets include CMF (cyclophosphamide,
xorubicin, and cyclophosphamide).
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role in melanoma, and that induction of immune response is
important for disease control both in the adjuvant and advanced
disease settings.9–14 As a result, immunotherapy has been widely
examined and chemotherapy has played a smaller role. Adjuvant
therapy is accepted following resection of melanoma at high risk
of recurrence (stage IIB–III) (Table 1). Currently, only interferon-
a2b (IFN-a2b) is approved worldwide for melanoma while inter-
feron-a2a (IFN-a2a) is approved in Europe and pegylated
IFN-a2b (PEG-IFN-a2b) was recently approved in the US. IFN-a
dosing regimens vary but have had uniform, signiﬁcant beneﬁts
upon relapse and smaller beneﬁts upon survival.
Most patients with operable breast cancer are considered candi-
dates for systemic adjuvant therapy. Compared with the other
solid tumors discussed here, adjuvant therapy for breast cancer
has been longer established and more broadly accepted, with re-
cent progress in terms of personalized application of therapy
according to individual characteristics of each patient’s tumor.
Options include cytotoxic, endocrine, and/or targeted anti-HER2
therapy. The criteria for treatment selection are summarized in
Table 1.15 The predictive factors that are useful for patient and phy-
sician decision-making are well deﬁned: estrogen receptor (ER)
and HER2/neu oncogene expression16,17 are used to select candi-
dates for endocrine or anti-HER2-directed therapy, respectively.
Tamoxifen is the preferred endocrine therapy for ER and/or proges-
terone receptor-positive disease in pre- and perimenopausal
women. For postmenopausal women, aromatase inhibitors (AIs)
are recommended either as initial endocrine therapy for 5 years,
or sequentially following a 2–5 year course of tamoxifen. Adjuvant
anti-HER2 therapy is indicated for any patient with HER2/neu over-
expressing disease who has a sufﬁciently high risk of recurrence to
justify the use of adjuvant chemotherapy (as described below).
HER2/neu overexpression is commonly deﬁned by criteria estab-
lished by the American Society of Clinical Oncology/College of
American Pathologists (ASCO-CAP) guidelines.18
Beyond the selection of hormonal and targeted therapeutic
agents, the application of adjuvant chemotherapy is generally
decided based upon the risk of recurrence, as in the majority of so-
lid tumors.17 Adjuvant chemotherapy is recommended for patients
with stage I–III breast cancer, including those with axillary lymph
nodes positive for tumor or for those with negative nodes and a
primary tumor >1 cm. The choice of regimen is individualized
based upon each patient’s underlying estimated risk of recurrence,
their comorbidities, and likely tolerance of toxicity. Anthracyclines,
alkylating agents, and taxanes are commonly used components,19
including sequential therapy (e.g., an anthracycline/cyclophospha-
mide doublet followed sequentially by a taxane) or concurrent
therapy (e.g., docetaxel/doxorubicin/cyclophosphamide). In some
circumstances, a non-anthracycline regimen may be considered
(e.g., docetaxel/cyclophosphamide or cyclophosphamide/metho-
trexate/5FU).Clinical trial data supporting adjuvant therapy
Non-small-cell lung cancer
The use of chemotherapy as adjuvant therapy in NSCLC is well
supported by clinical trial data. The ﬁrst meta-analysis of adjuvant
chemotherapy was published in 1995 by the NSCLC Collaborative
Group.20 Subset analysis of eight trials demonstrated a 13% overall
reduction in the risk of death and a trend towards improved sur-
vival at 5 years with cisplatin-based therapy; the absolute beneﬁt
of therapy was 5% (not statistically signiﬁcant [NS]; p = 0.08). This
work prompted an extensive evaluation of adjuvant cisplatin-
based chemotherapy in NSCLC.In the ALPI trial,21 1209 patients with completely resected stage
I–IIIA NSCLC were randomized to surgery alone, or surgery then
adjuvant mitomycin C, vindesine, and cisplatin. There was no sta-
tistically signiﬁcant difference between the two groups in OS (haz-
ard ratio [HR] = 0.96; 95% conﬁdence interval [CI] 0.81–1.13;
p = NS) but a trend towards improved disease-free survival (DFS)
in the chemotherapy arm (HR = 0.89; 95% CI 0.76–1.03; p = NS)
with an absolute beneﬁt of 7.6 months (95% CI –1.5 to 16.6). The
lack of statistical signiﬁcance was attributed in part to poor com-
pliance, as only 69% of patients received all three cycles of therapy.
However, multiple trials following ALPI have reported statistically
signiﬁcant improvements in outcomes with adjuvant chemother-
apy.22–24 The IALT included 1867 patients with resected stage I–
III NSCLC who were randomized to a cisplatin-based regimen or
observation alone.22 The trial was stopped early due to declining
enrollment rates, attributed to emerging interest in neoadjuvant
therapy. Despite early closure, 5-year OS was 40.4% with surgery
alone and 44.5% with surgery and adjuvant therapy (HR = 0.86;
95% CI 0.76–0.98; p < 0.03); median OS was 44 and 50 months,
respectively. An update of IALT based on median follow-up of
7.5 years reported that the OS and DFS beneﬁts were maintained
up to 5 years, but suggested an increase in non-cancer-related
deaths with chemotherapy compared with observation after this
point.25 The National Cancer Institute of Canada JBR.10 trial ran-
domly assigned 482 patients with completely resected earlier
stage IB or II (excluding T3N0) NSCLC to four cycles of cisplatin plus
weekly vinorelbine or observation.23 Five-year OS was 69% with
chemotherapy vs. 54% with observation (p = 0.03). This translated
to an absolute beneﬁt of 15% in 5-year OS for cisplatin-based adju-
vant therapy. Updated survival data from JBR.10 at 9 years’ follow-
up reported that the statistically signiﬁcant survival beneﬁts of 11%
with adjuvant therapy vs. observation were maintained over time
(5-year OS 67% vs. 56%, respectively; HR = 0.78; 95% CI 0.61–0.99;
p = 0.04).26 The ANITA trial compared adjuvant cisplatin and vino-
relbine with observation in 799 patients with stage IB–IIIA
NSCLC.24 Median OS was 44 months with observation and
66 months with adjuvant therapy (HR = 1.26; 95% CI 1.05–1.52;
p = 0.013). Five-year OS was 51% vs. 43% with chemotherapy and
observation, respectively, and the beneﬁt was sustained at 7 years.
Given the toxicity and poor tolerability of cisplatin, there has
been interest in substituting it with carboplatin for adjuvant treat-
ment. The Cancer and Leukemia Group B (CALGB) compared carbo-
platin and paclitaxel (n = 173) to observation alone (n = 171) in
patients with stage IB NSCLC.27 Preliminary analysis noted signiﬁ-
cantly improved OS at 4 years (71% with carboplatin vs. 59% obser-
vation) and the trial was closed early. However, at 74 months’
follow-up the difference in OS was no longer statistically signiﬁ-
cant, although the HR remained the same (HR = 0.83; 95% CI
0.64–1.08; p = 0.12). Patients treated with carboplatin had a 5-year
OS of 60% vs. 58% with observation (p = 0.190). Multiple factors,
including small sample size (n = 344) and restriction to stage IB
NSCLC could have contributed to these results. Prior trials have
noted relatively small beneﬁts for stage IB disease, so this study
may have been underpowered. Based upon this trial, it is generally
accepted that carboplatin cannot be used in lieu of cisplatin,
although it is still to be considered with paclitaxel in patients at
high risk for cisplatin toxicity. The role of taxanes requires further
study.
The major toxicities associated with the cisplatin and vinorel-
bine combination in ANITA included grade 3 or 4 neutropenia
(85%), febrile neutropenia (9%), nausea and vomiting (27%), consti-
pation (5%), and neuropathy (3%). The incidence of chemotherapy-
related death was 2%. In JBR.10 the major toxicities included grade
3 or 4 neutropenia (73%), febrile neutropenia (7%), fatigue (15%),
vomiting (10%), and anorexia (10%). Assessment of a subset of
patients from this trial demonstrated a slight decrease in the
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the quality of life-adjusted survival was higher in the adjuvant
therapy arm, despite toxicity.28 The direct cost of adjuvant therapy,
including supportive care, emergency room visits, surgery, and
radiology, was assessed in a subset analysis of 172 patients from
JBR.10. The average cost of adjuvant therapy was $31,319 vs.
$23,878 in the observation arm, with a very favorable incremental
cost effectiveness ratio of $7175 per life-year gained. However, this
analysis only considered treatment in Canada, and health care
costs and standard practices differ in other countries.29Table 2
Summary table of recent adjuvant chemotherapy trials in stage II and III resected colon c
Trial Study patients Treatment
IMPACT30 Duke B + C
n = 1493
5FU 370–400 mg/m2 + folinic acid 20
q28 days  6 months
vs. observation
MOSAIC31 Stage II + III
n = 2246
FOLFOX4  6 months
vs. FU5LV  6 months
NSABP C-0732 Stage II + III
n = 2409
FULV + oxaliplatin 85 mg/m2 weeks 1
vs. FULV  3 cycles
QUASAR33 Surgically resected
(90% stage II)
n = 3239
5FU 370 mg/m2 + LV 25 or 175 mg/m
weekly  30 5FU treatments
vs. observation
X-ACT34 Stage III
n = 1987
Capecitabine 1250 mg/m2 PO BID da
vs. 5FU 425 mg/m2 + LV 20 mg/m2 b
q28 days  6 cyclesb
XELOXA35 Stage III
n = 1886
XELOX  8 cycles
vs. FULV or Mayo
ACCORD-0236 Stage III
n = 400
FU5LV + irinotecan 180 mg/m2 day 1
vs. FU5LV  6 months
CALGB 8980337 Stage III
n = 1264
LV 20 mg/m2 + 5FU 500 mg/m2 + irin
for 4 weeks q6 weeks  5 cycles
vs. FULV  4 cycles
PETACC 338 Stage II + III
n = 3278
FU5LV + irinotecan 180 mg/m2 day 1
(or LV 500 mg/m2 + 5FU 2000 mg/m2
80 mg/m2 weekly for 6 weeks q8 we
vs. FU5LV or alternative
NSABP C-0839 Stage II + III
n = 2672
mFOLFOX6  6 months
vs. mFOLFOX6  6 months + bevacizu
AVANT40 Stage II + III FOLFOX4  6 months
vs. FOLFOX4 + bevacizumab 5 mg/kg
by bevacizumab 7.5 mg/kg q3 weeks
vs. XELOX + bevacizumab 7.5 mg/kg
bevacizumab 7.5 mg/kg q3 weeks  6
Intergroup N014741 Stage III mFOLFOX6 + cetuximab 250 mg/m2 (
q2 weeks  6 months
vs. mFOLFOX6  6 months
5FU, 5-ﬂuorouracil; LV, leucovorin; NS, not signiﬁcant; NA, not applicable or not report
FULV = 5FU 500 mg/m2 + LV 500 mg/m2 bolus weekly for 6 weeks q8 weeks.
FU5LV = LV 200 mg/m2 + 5FU 400 mg/m2 bolus, followed by 5FU 600 mg/m2 22 h infusi
FOLFOX4 = FU5LV + oxaliplatin 85 mg/m2 day 1 q14 days  6 months.
mFOLFOX6 = LV 400 mg/m2 + 5FU 400 mg/m2 + oxaliplatin 85 mg/m2 day 1 followed by
Mayo = 5FU 500 mg/m2 + LV 20 mg/m2 bolus weekly  30 treatments.
XELOX = capecitabine and oxaliplatin.
a Includes stage II and III patients. Stage II patients: no overall survival advantage, sta
b Non-inferiority trial design.
c For stage III only. Stage II 5-year disease-free survival and overall survival are NS, b
d No disease-free survival beneﬁt for the addition of bevacizumab.Colon cancer
Relevant studies of adjuvant therapy in resected colon cancer
are summarized in Table 2.30–41 Adjuvant 5FU/LV for stage III dis-
ease was originally supported by an Intergroup study42,43 and later
by IMPACT,30 a pooled analysis of three prospective studies includ-
ing 4000 patients with stage II–III colon cancer. This revealed a
signiﬁcant improvement in 3-year DFS. In addition, the X-ACT
study34 established the non-inferiority of 6 months of capecitabine
compared with 5FU/LV, with trends towards improvement in
3-year DFS and OS in stage III patients. In MOSAIC31,44 the additionancer.
Disease-free survival Overall survival
0 mg/m2 daily days 1–5 3 year
71%
(p < 0.001)
3 year
83%
(p = 0.029)
62% 78%
5 year
73.3%
(p = 0.003)
6 yeara
78.5%
(p = 0.046)
67.4% 76%
, 3, and 5 q8 weeks  3 cycles 8 year
69.4%
(p = 0.002)
8 year
80.2%
(p = 0.08)
64.2% 78.4%
2 days 1–5 q28 days or NA 5.5 year
HR = 0.82
(p = 0.008)
ys 1–14 q21 days  8 cycles 3 year
64.2%
(p = 0.12)
3 year
81.3%
(p = 0.05)
olus days 1–5 60.6% 77.6%
3 year
70.9%
(p = 0.0045)
5 year
77.6%
(p = NS)
66.5% 74.2%
q14 days  6 months 3 year
51%
(p = 0.22)
5 year
61%
(p = 0.26)
60% 67%
otecan 125 mg/m2 weekly 5 year
59%
(p = 0.85)
5 year
68%
(p = 0.74)
61% 71%
q14 days  6 months
over 24 h + irinotecan
eks  4 cycles)
5 yearc
56.7%
(p = 0.106)
5 yearc
73.6%
(p = 0.094)
54.3% 71.3%
mab 5 mg/kg q2 weeks  1 year
3 year
HR = 0.89
(p = 0.15)
NA
q2 weeks  6 months followed
alone  6 months
q3 weeks  6 months followed by
months
NSd NA
initial dose 400 mg/m2) NS NA
ed.
on day 1 and day 2 q14 days.
5FU 2400 mg/m2 over 46 h q2 weeks.
ge III patients 72.9% vs. 68.7%; p = 0.023.
ut pooled stage II + III patients disease-free survival is signiﬁcant (p = 0.045).
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advantages vs. 5FU/LV in stage II–III patients, particularly evident
in stage III disease. NSABP C-0745 enrolled a similar patient
population, ﬁnding a 5% absolute DFS beneﬁt at 5 years with the
addition of oxaliplatin to 5FU/LV-based therapy, although 8-year
OS data did not show a survival advantage with oxaliplatin.32
The addition of oxaliplatin to capecitabine (XELOX) was successful
in XELOXA,35 a European phase III randomized study comparing
XELOX to bolus regimens of 5FU/LV for resected stage III patients,
ﬁnding superiority of XELOX in 3-year DFS.
The use of 5FU/LV in stage II disease is common in the oncology
community but has not been validated in prospective randomized
trials. The QUASAR33 study revealed a small, statistically signiﬁcant
beneﬁt of 5FU/LV over observation in stage II disease (absolute OS
beneﬁt 3.6%), but other studies,46,47 and a systematic review,48 as
well as a further pooled analysis by IMPACT investigators49 includ-
ing 1600 stage II patients from ﬁve prospective trials did not ﬁnd
DFS or OS beneﬁts. MOSAIC44revealed only a trend towards im-
proved DFS with the addition of oxaliplatin to 5FU/LV in subset
analyses of stage II (node negative) disease. An update of MOSAIC31
revealed a trend toward 5-year DFS advantage with the addition of
oxaliplatin in high-risk stage II disease (T4 lesions, poorly differen-
tiated histology, venous invasion, perforation, obstruction, <10
lymph nodes examined) based on exploratory subset analyses,
but no survival advantage. In NSABP C-07,45 DFS favored the addi-
tion of oxaliplatin but this difference was not signiﬁcant in node-
negative patients using multivariate analysis. A recently published
retrospective database review found no 5-year survival beneﬁt
with adjuvant chemotherapy in stage II patients with or without
poor prognostic features.50 Currently, there are no prospective,
high quality studies speciﬁcally in high-risk stage II disease that
demonstrate a DFS or OS advantage with adjuvant chemotherapy.
Thus, routine use of oxaliplatin is not recommended in stage II
patients and treatment with single agent 5FU/capecitabine needs
to involve a detailed risk/beneﬁt discussion.
Acute toxicity with FOLFOX includes myelosuppression, fatigue,
nausea, diarrhea, mucositis, and hand-foot syndrome. The modest
but statistically signiﬁcant beneﬁt of adding oxaliplatin in stage III
disease should be considered in balance with the 40% risk of
chronic neuropathy51 and 10-50% risk of chronic hepatotoxicity
with vascular sinusoidal injury52 that may occur with this agent.
In addition, NSABP C-0732 and the ACCENT database53 raised con-
cerns that older patients may not derive a survival beneﬁt from the
addition of oxaliplatin to a 5FU based regimen, although contrary
data exists.35,54 Acute oxaliplatin neurotoxicity occurs in 65–98%
of patients,55 often beginning during infusion and peaking hours
or days later.56 It is characterized by symptoms including cold-in-
duced dysesthesias and paresthesias of the upper extremities and
face, cold hypersensitivity, jaw tightness, pharyngolaryngeal
dysesthesia (loss of sensation of breathing without any objective
evidence of respiratory distress), muscle spasms, fasciculations,
voice changes, and ocular pain.57–63 Risk of chronic neuropathy,
but not acute neurotoxicity, can be reduced by 50% with calcium
and magnesium infusions given pre- and post-oxaliplatin.51 In
terms of adjuvant treatment costs in the US for stage III colon can-
cer, the lifetime expense of FOLFOX was higher than that of 5FU/LV
($56,320 versus $39,285). The ratio of cost per quality-adjusted
life-year (QALY) gained was very acceptable at $22,804.64
Sarcoma
Osteosarcoma is the most common primary malignant bone
cancer. Evidence for the therapeutic beneﬁt of chemotherapy
emerged in the 1970s, with improvements in RFS compared with
amputation noted in non-controlled trials.65–68 RCTs conﬁrmed a
signiﬁcant reduction in recurrence risk and improved survival inpatients with localized disease.69,70 The T10 protocol (methotrex-
ate, doxorubicin, cyclophosphamide, dactinomycin, and bleomy-
cin) led to a 5-year DFS rate of 76% compared with historic
survival rates of around 20% in patients having surgery alone.71 A
randomized trial conducted by the European Osteosarcoma Inter-
group suggested that doxorubicin 75 mg/m2 and cisplatin
100 mg/m2 for six cycles had comparable DFS and OS beneﬁts com-
pared with the more complicated and protracted T10 chemother-
apy regimen, with greater likelihood of being fully delivered.72
Several subsequent studies examined the omission of doxorubicin
and/or cisplatin, concluding that both agents are necessary.73–75
The combination of ifosfamide and etoposide (IE) has emerged as
an active, alternative regimen in advanced osteosarcoma.76,77
Ewing’s sarcoma accounts for 10–15% of malignant bone sarco-
mas.78 The ﬁrst Intergroup Ewing’s Sarcoma Study (IESS) showed a
clear advantage for the addition of doxorubicin to cyclophospha-
mide, dactinomycin, and vincristine in patients with tumors local-
ized in an extremity.79 The second IESS showed a survival
advantage for cyclophosphamide 1400 mg/m2 administered every
3 weeks compared with cyclophosphamide 500 mg/m2 given
weekly.80 The addition of IE to cyclophosphamide, doxorubicin,
and vincristine signiﬁcantly improved 5-year event-free survival
(EFS) and OS for patients with localized disease.7 This study con-
ﬁrmed previous ﬁndings that presence or absence of metastases
and tumor size were important prognostic factors for EFS and OS.
Speciﬁcally, a pelvic site had a 50% EFS compared with 68% and
61% among patients with tumors of the distal extremity and prox-
imal extremity, respectively (p = 0.003). Age was also conﬁrmed to
be predictive of a worse outcome in older patients (patients
P18 years vs. <10 years, relative risk [RR] = 2.5; p = 0.001).7
Ewing’s tumors are sensitive to ionizing radiation, providing local
control without surgery in up to 30% of patients, which is germane
for pelvic tumors.7,81
STS comprise at least 50 different histologic subtypeswith a het-
erogeneous clinical course largely determined by the tissue of origin
and tumor grade. Several clinicopathologic factors predict poor out-
come in STS, including tumor grade, size, and relationship to fascia;
large, high-grade, deep tumors recur resulting in death in over 50%
of patients despite local control.82–85 Clinical evidence is limited but
the ﬁndings suggest beneﬁt with adjuvant doxorubicin and
ifosfamide for patients with high-risk STS, particularly involving
an extremity. Early adjuvant trials were conducted with doxorubi-
cin alone or combined with radiation therapy.86,87 The addition of
ifosfamide resulted in signiﬁcantly higher response rates for
advanced/metastatic sarcoma than doxorubicin alone.88 Conﬂicting
data are available from small, randomized trials accumulated over
two decades.89–92 These conﬂicting data, and the lack of feasibility
of a large adjuvant trial to prove small but clinically signiﬁcant
beneﬁts, led to the use of meta-analysis.93,94 The Sarcoma Meta-
Analysis Collaboration (SMAC) pooled individual patient data from
1568 patients enrolled on 14 trials. SMAC found beneﬁt from doxo-
rubicin-based adjuvant chemotherapy, with a 27% RR reduction for
local relapse at 10 years (6% absolute beneﬁt), and a 30% RR reduc-
tion for distant metastasis (10% absolute beneﬁt), while there was
an 11% RR reduction in death corresponding to an absolute survival
beneﬁt of 4% at 10 years, although the HR for OS did not reach sig-
niﬁcance (0.89 [95% CI 0.76–1.03]; p = 0.12).95 Patients with high-
grade extremity STS had a slightly higher absolute survival beneﬁt
of 7% at 10 years.95 The most recent update included a total of
1953 patients from 18 trials, reﬂecting the results of modern ifosfa-
mide-containing regimens, and conﬁrmed small but statistically
signiﬁcant beneﬁts from adjuvant chemotherapy on all measures
of local and distant recurrence as well as OS.96 Overall the data sug-
gest only modest effects of adjuvant therapy on OS in STS and the
risk/beneﬁt ratio should therefore be considered on a case by case
basis.
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coma and Ewing’s sarcoma; however, the long-term sequelae of
chemotherapy must be considered. Long term follow-up has re-
vealed that survivors of childhood Ewing’s sarcoma have increased
mortality unrelated to recurrence, and are at substantially higher
risk of infertility and other morbidity, including second malignan-
cies, chronic health conditions, and functional impairment.97,98 In
STS, the addition of ifosfamide to doxorubicin-based chemother-
apy imparted additional beneﬁts but came at increased risk of
toxicity;96 doxorubicin and ifosfamide are associated with well-
documented cardiac and renal toxicity.
Melanoma
Melanoma is highly curable by surgery when treated early, but
may carry a lethal prognosis when inoperable.99,100 The best
opportunity for cure through systemic medical therapy lies in the
postoperative adjuvant setting among patients at high risk for
recurrence and death (Stage IIB–III). More than 20 trials of IFN-a
worldwide have evaluated the optimal dose, schedule, and dura-
tion of therapy. There is overall agreement and consistent evidence
for a signiﬁcant improvement of RFS with IFN-a at high and inter-
mediate doses in multiple clinical trials and meta-analyses; the OS
effects have been less clear cut.101–107 Meta-analysis of 12 random-
ized adjuvant trials was therefore pursued and conﬁrmed highly
signiﬁcant reduction in recurrence with IFN-a over observation
and a trend towards improved beneﬁt with increasing dosage.107
A larger individual patient data meta-analysis of 13 randomized
trials showed a statistically signiﬁcant beneﬁt for event-free sur-
vival (EFS) (odds ratio [OR] = 0.87; 95% CI 0.81–0.93; p = 0.00006)
and a signiﬁcant, smaller overall impact upon OS (OR = 0.9; 95%
CI 0.84–0.97; p = 0.008),106 corresponding with an absolute sur-
vival beneﬁt of 3% (95% CI 1–5%) at 5 years.106 The largest
meta-analysis of 14 published adjuvant RCTs105 showed statisti-
cally signiﬁcant improvements in both DFS and OS. Adjuvant
IFN-a or PEG-IFN-a2b signiﬁcantly improved DFS in 10 of 17 com-
parisons (disease recurrence HR = 0.82; 95% CI 0.77–0.87;Table 3
Therapeutic beneﬁt from adjuvant systemic therapies in breast cancer.
Intervention Comparison Follow-up
Chemotherapy Polychemotherapy vs. none
<50 years At 15 yea
P50 years At 15 yea
Anthracycline-based chemotherapy vs. nonea At 10 yea
CMF chemotherapy vs. nonea At 10 yea
Taxane vs. non-taxane containing chemotherapy Median o
5 years
Taxane + anthracycline-based regimen vs.
anthracycline-based controla
Median o
8 years
Endocrine
therapy
Tamoxifen vs. none At 15 yea
AI vs. tamoxifen for 5 years Median o
5.8 years
Tamoxifen for 2–3 years followed by an AI vs. tamoxifen
for 5 years
Median o
3.6 years
Trastuzumab Chemotherapy plus trastuzumab vs. no trastuzumab Median o
2 years
CI, conﬁdence intervals; CMF, cyclophosphamide/methotrexate/5FU; EBCTCG, Early Brea
a Relative risk reported (not hazard rate).p < 0.001) and improved OS in four of 14 comparisons (death
HR = 0.89; 95% CI 0.83–0.96; p = 0.002) corresponding with an
18% improvement in DFS and 11% improvement in OS.105 The Euro-
pean Organisation for Research and Treatment of Cancer (EORTC)
trial 18991 compared observation with an intended 5 years of
maximally tolerable doses of PEG-IFN-a2b for resected stage III
melanoma (TxN1–2M0).108 PEG-IFN-a2b was administered at
6 lg/kg/week for 8 weeks followed by 3 lg/kg/week maintenance
for up to 5 years. There was early improvement in RFS
(HR = 0.82; p = 0.01) at 3.8 years median follow-up but no signiﬁ-
cant improvement in OS or distant metastasis-free survival (DMFS)
at 3.8 years median follow-up. The improvement in RFS was
diminished at the 7.6 year follow-up reported in 2011 (HR = 0.87;
95% CI 0.76–1.00; p = 0.05).109
High-dose IFN-a2b is associated with substantial toxicity; this
can lead to discontinuation of the recommended 1-year regimen
among 10–26% of patients, although most toxicity is manageable
with dose reductions and supportive care.110 The toxicity proﬁle
has been shown to be manageable by experienced medical oncol-
ogists, with a toxicity attrition rate of only 10% in the largest Inter-
group trial of high-dose IFN-a2b (E1694).102 The most common
side effects are ﬂu-like syndrome (e.g., fatigue, fever, myalgia,
and nausea), myelosuppression, hepatotoxicity, and depression.
Intermediate doses have been pursued to reduce toxicity, often
for longer than 1 year. Although the meta-analyses have not clari-
ﬁed an optimum dose or duration, DFS beneﬁts appear to be great-
er and more durable with high-dose IFN-a2b than with
intermediate or low doses at >5 years of follow up. PEG-IFN-a2b
has a more convenient dosing schedule than IFN-a2b, requiring
weekly administration. The toxicity proﬁle is similar; however,
the most common side effects are fatigue, hepatotoxicity, fever,
headache, anorexia, myalgia, nausea, chills, injection site reactions,
and depression.108 The toxicity and ﬁnancial cost of therapy has
prompted the search for identiﬁers of patient groups that are most
likely to beneﬁt from adjuvant therapy and is the subject of ongo-
ing research. There is evidence of higher levels of pro-inﬂamma-
tory cytokines in the pretreatment serum of patients who remainHazard rate for disease-free
survival
Hazard rate for overall
survival
Reference
EBCTCG116
rs 0.63 (SE ± 0.02)
p < 0.00001
0.71 (SE ± 0.04)
p < 0.00001
rs 0.81 (SE ± 0.02)
p < 0.00001
0.88 (SE ± 0.03)
p < 0.00001
rs 0.73 (SE ± 0.03)
p < 0.00001
0.84 (SE ± 0.03)
p < 0.00001
EBCTCG117
rs 0.70 (SE ± 0.04)
p < 0.00001
0.84 (SE ± 0.05)
p = 0.0004
f 0.86
(95% CI 0.81–0.91)
p < 0.00001
0.87
(95% CI 0.81–0.93)
p < 0.0001
Bria et al.118
f 0.86 (SE ± 0.02)
p < 0.00001
0.89 (SE ± 0.03)
p < 0.00001
EBCTCG117
rs 0.61
(SE ± 0.04)
p < 0.0001
0.69
(SE ± 0.05)
p < 0.0001
EBCTCG116
f 0.77
(SE ± 0.05)
p < 0.0001
0.94
(SE ± 0.06)
p = NS
Dowsett
et al.119
f 0.71
(SE ± 0.060)
p < 0.0001
0.79
(SE ± 0.07)
p = 0.04
Dowsett
et al.119
f 0.53
(95% CI 0.46–0.60)
p < 0.00001
0.52
(95% CI 0.44–0.62)
p < 0.00001
Viani
et al.120
st Cancer Trialists’ Collaborative Group; SE, standard error.
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younger members of society in their most productive years, the
relative societal cost of this solid tumor eclipses that of many other
solid tumors. A cost-beneﬁt analysis following the initial regula-
tory approval of high-dose IFN-a2b showed costs that compare
favorably with accepted standards of cost per year of life gained
in non-malignant diseases.112,113
Breast cancer
Breast cancer mortality decreased in the United States for the
ﬁrst time in 2000,114 which has been attributed in part to improve-
ments in adjuvant therapy.115 The speciﬁc beneﬁts for each inter-
vention for this solid tumor are summarized in Table 3.116–120
Adjuvant chemotherapy
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
reported that adjuvant polychemotherapy reduced the risk of
recurrence and death substantially after 15 years of follow-up,
with greater relative beneﬁts among younger women (<50 years)
compared with older women (50–69 years), but similar beneﬁts
otherwise, irrespective of tamoxifen use, ER status, nodal status,
or other tumor characteristics.116 An update of the EBCTCG meta-
analysis indicated that the standard chemotherapy regimens of 4
cycles of doxorubicin/cyclophosphamide (4AC) and 6 cycles of
cyclophosphamide/methotrexate/5FU (CMF) were equivalent in
terms of breast cancer mortality (RR = 0.98 [SE = 0.05]; two-sided
signiﬁcance [2p] = 0.67).117 However, anthracycline-based regi-
mens with a substantially higher cumulative dosage than standard
4AC (e.g., 6 cycles of cyclophosphamide/doxorubicin/5FU [CAF] or
cyclophosphamide/epirubicin/5FU) were associated with lower
breast cancer mortality than standard CMF (RR = 0.78 [SE = 0.06];
2p = 0.0004). There were greater reductions in breast cancer
mortality with CAF versus no chemotherapy (RR = 0.64
[SE = 0.09]; 2p < 0.0001) than with standard 4AC (RR = 0.78
[SE = 0.09]; 2p = 0.01) or standard CMF (RR = 0.76 [SE = 0.05];
2p < 0.0001) versus no chemotherapy. Other analyses with shorter
follow-up suggested less beneﬁt for ER-positive disease, which
may reﬂect an effect of chemotherapy in preventing early recur-
rence, which characterizes ER-negative disease.121 There is little
information about chemotherapy use in women P70 years old.
Multiple individual studies have shown that taxanes adminis-
tered every 3 weeks either concurrently (docetaxel)122 or sequen-
tially (paclitaxel)123,124 after anthracycline-containing therapy
further reduced the risk of recurrence and death. Interpretation
of initial studies was confounded by longer duration of therapy
for the taxane arms (eight treatment cycles over 24 weeks) com-
pared with non-taxane arms (four cycles over 12 weeks);123,124
subsequent studies conﬁrmed a beneﬁt for the sequential anthra-
cycline–taxane strategy when the comparator arm included anth-
racyclines given alone for a comparable duration.125,126 A single
study involving 1016 patients with 0–3 positive axillary nodes
demonstrated that four cycles of the TC regimen (docetaxel
75 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks) was
associated with signiﬁcantly improved DFS and OS compared with
four cycles of standard anthracycline-based chemotherapy
(doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every
3 weeks).127 A meta-analysis of phase III randomized trials includ-
ing >15,500 patients conﬁrmed that taxane-based adjuvant
chemotherapy signiﬁcantly improves both DFS and OS (Table 3),
with absolute beneﬁts of 3.3% and 2.0%, respectively.118 In concor-
dance with this, the updated EBCTCG meta-analysis found a reduc-
tion in breast cancer mortality with taxane plus anthracycline
regimens versus anthracycline control regimens (RR = 0.87 [SE
0.03]; 2p < 0.00001) (Table 3).117 The EBCTCG also found thatextending treatment duration by adding four separate cycles of a
taxane to a ﬁxed anthracycline-based control regimen reduced
breast cancer mortality (RR = 0.86 [SE = 0.04]; 2p = 0.0005),
although similar beneﬁts were not seen in this meta-analysis when
the four additional taxane cycles were offset with extra cycles of
non-taxane regimens to effectively double the non-taxane dose
(RR = 0.94 [SE = 0.06]; 2p = 0.33). Proportional risk reductions with
taxane-based regimens were not inﬂuenced by age, nodal status,
tumor size, grade, estrogen receptor status, or tamoxifen use. Pac-
litaxel appears to be more effective when given weekly for 8–12
cycles compared with every 3 weeks for 4 cycles,128 and when gi-
ven twice weekly in a dose-dense schedule for four cycles as part of
a sequential anthracycline–cyclophosphamide–taxane regimen
compared with the same agents given every 3 weeks for four cy-
cles.129 In contrast, other studies have not shown beneﬁts for
dose-dense schedules of other chemotherapy regimens (concur-
rent 5FU, epirubicin, cyclophosphamide).130
Common reversible toxicity of adjuvant chemotherapy includes
alopecia, myelosuppression, and fatigue, although other adverse
effects such as neuropathy associated with taxanes may persist.
Delayed effects associated with anthracyclines include cardiomy-
opathy and acute leukemia, although these are uncommon.
Adjuvant endocrine therapy
A 5-year course of the selective estrogen receptor modulator
tamoxifen was previously considered standard therapy for patients
with ER-positive disease, including pre-, peri-, and postmeno-
pausal women. Several trials failed to demonstrate greater beneﬁt
from a 10-year course.131–134 Tamoxifen remains the preferred
endocrine therapy in pre- and perimenopausal women. Aromatase
inhibitors (AIs) are also an option for postmenopausal women in
whom the ovaries no longer serve as a source of endogenous estro-
gen. Several large, randomized, phase III trials in postmenopausal
women have evaluated AIs as initial adjuvant endocrine therapy
compared with tamoxifen,135,136 as sequential therapy after
2–3 years of tamoxifen (compared with continued tamoxi-
fen),137–139 or as extended adjuvant therapy after 5 years of
tamoxifen.140–143 Based upon these studies, an American Society
of Clinical Oncology (ASCO) expert panel has recommended that
a strategy incorporating an AI as initial endocrine therapy for
5 years, an AI sequentially following 2–3 years of tamoxifen (for
a total of 5–7.5 years), or an AI after 5 years of tamoxifen (for a
total of 10 years), because each of these strategies has been shown
to reduce the risk of recurrence compared with 5 years of tamoxi-
fen alone.119,144 Tamoxifen and AIs differ in their adverse effect
proﬁles, and these differences may inform treatment preferences.
Tamoxifen is associated with more thromboembolic events, endo-
metrial pathology, hot ﬂushes, night sweats, and vaginal bleeding,
whereas AIs are associated with more arthralgias and bone frac-
tures. AIs may also reduce recurrence when initiated well after
completion of a 5-year course of adjuvant tamoxifen.142 AIs should
be used only in postmenopausal women because they block the
conversion of androgen into estrogen by aromatase in tumor and
peripheral tissues145 rather than preventing estrogen production
by the ovaries. In women with chemotherapy-induced amenorrhea
lasting <1–2 years, estradiol and follicle stimulating hormone
levels should be obtained in order to conﬁrm menopause prior to
initiating an AI.146
Adjuvant anti-HER2 therapy
Trastuzumab is a humanized monoclonal antibody directed
against the HER2/neu protein, and was approved for the treatment
of HER2-positive metastatic disease when it was shown to prolong
survival and improve response and time to disease progres-
sion.147,148 Five randomized trials including patients with HER2-
positive disease compared chemotherapy alone or in combination
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early stage disease.120,149–152 Pooled results from these trials
demonstrated signiﬁcant reductions in recurrence (HR = 0.53;
p < 0.00001) and death (HR = 0.52; p < 0.00001) for trastuzumab,
accompanied by more grade 3–4 cardiac toxicity (4.5% vs. 1.8%).120Lessons learned from adjuvant therapy
A number of valuable lessons have been learned during the
application of adjuvant therapy in the solid tumors described here.
This section discusses the data supporting the following ﬁndings:
(1) Beneﬁt of an agent in the metastatic setting does not necessar-
ily guarantee beneﬁt in the adjuvant setting; (2) We should avoid
the use of unplanned, underpowered subset analyses, and avoid
the extrapolation of promising early data from studies that closed
prematurely, to predict beneﬁt; (3) In colon cancer, a statistically
signiﬁcant beneﬁt in DFS after 3 years’ follow-up generally trans-
lates into a statistically signiﬁcant survival beneﬁt after 5–6 years’
follow-up.
In the absence of major differences among chemotherapy dou-
blets used for advanced NSCLC, many clinicians have extrapolated
advanced disease data to earlier stage disease, and use ‘‘third gen-
eration’’ cytotoxic drugs in combination with cisplatin (such as
pemetrexed, docetaxel, and gemcitabine) – albeit without Level 1
data. In melanoma, the ﬁrst survival-improving agents, including
anti-CTLA-4 immunotherapy and molecularly targeted inhibitors
of mutated BRAFV600E, have rapidly entered evaluation in the
adjuvant setting following their success and regulatory approval
in advanced disease. However, studies in other solid tumors such
as colorectal cancer suggest that this paradigm may not translate
from advanced to adjuvant arenas. In colon cancer, this approach
was successful in some cases but a failure in others. The addition
of oxaliplatin chemotherapy to 5FU-based therapy or capecitabine
was successful, with beneﬁts in advanced disease that translated to
the adjuvant setting (Table 2);35,44 however, three promising
agents that were shown to be of use in advanced colon cancer
(the cytotoxic agent irinotecan, and anti-angiogenic/molecularly
targeted agents bevacizumab and cetuximab) did not improve out-
comes when added to FOLFOX regimens in the adjuvant setting.
Three large, randomized, phase III studies (ACCORD-02,36 CALGB
89803,37 and PETACC-338) revealed neither DFS nor OS beneﬁts
in stage III disease with irinotecan/5FU/LV vs. 5FU/LV alone. Fur-
thermore, NSABP C-08,39 AVANT,40 and Intergroup N014741 re-
vealed no additional beneﬁt of adding bevacizumab or cetuximab
to standard chemotherapy in the adjuvant setting, although more
mature follow-up may be needed to determine the long-term ef-
fects of the added biologics. These ﬁndings underscore the impor-
tance of conducting rigorous, adequately powered RCTs to directly
determine the efﬁcacy of new approaches in the adjuvant setting
or treatments that have beneﬁts in metastatic, inoperable disease.
It is not safe to assume that agents active in advanced disease will
have the same efﬁcacy in early, curative disease.
Caution should also prevail when attempting to infer the suc-
cess of adjuvant therapy based on unplanned, underpowered sub-
set data from patients selected from overall patient populations
evaluated in trials of adjuvant therapy (e.g., from Stage III to Stage
II), and when extrapolating initial promising results from trials that
have been stopped early. As discussed, 5FU/LV is used in stage II
colon cancer based on its efﬁcacy in stage III disease, but the ben-
eﬁt in stage II disease has not yet been conﬁrmed. In NSCLC, data
suggest that greater beneﬁts are seen in Stage II and IIIA when
compared with Stage Ib disease. There is also evidence that the
beneﬁt of adjuvant PEG-IFN-a2b in melanoma may be greater in
patients with microscopic (lower) nodal disease burden arising
from ulcerated primary melanoma compared with grossmacroscopic nodal disease, as detailed in the next section. These
potential differences should be the focus of prospective future re-
search trials. Similarly, although early prediction of OS rates in
clinical trials is desirable to speed the transition of new, effective
adjuvant therapies from trials into clinical use, long-term follow-
up remains essential to validate the results of trials in the adjuvant
setting more than any other setting. The IALT and CALGB NSCLC
studies were stopped early and initial results were promising.
However, in the CALGB trial the differences in OS lost statistical
signiﬁcance at longer follow up. In IALT, at a median follow-up of
7.5 years, cumulative lung cancer-related death rates still favored
the use of chemotherapy but noted an excess of non-cancer-related
deaths observed with chemotherapy compared with observation,
raising the question of detrimental long-term effects of chemo-
therapy.25 These losses of effect have not been reﬂected in long-
term follow up of the JBR.10 and ANITA trials. Reasons for these
differences in long-term outcomes are not clear, but may include
differences in patient populations, differences in chemotherapy
regimens used, use of postoperative radiation therapy, and differ-
ences in reporting causes of death.153 The similar loss of signiﬁ-
cance for trials of high-dose IFNa2b in melanoma has been
conjectured to be due to the potential occurrence of non-neoplastic
causes of mortality, since RFS has been preserved for more than
12.6 years but OS beneﬁts appear to erode after 10 years.103 How-
ever, in adjuvant trials for all solid tumors, these ﬁndings suggest
that longer term follow-up is needed to assess the true balance
of beneﬁt and risk from each of the diverse chemotherapy, hor-
monal, immunological and targeted therapies; consideration of
the long-term risks are increasing in correlation with increasing
survival times.25,153
For many solid tumors, the endpoint of new trials has been RFS
improvement; in others the more rigorous goal of improving OS
has been adopted, or RFS and OS have been evaluated as coprimary
endpoints. As clinical trials of adjuvant therapy require long follow
up to determine OS beneﬁts, it would be desirable to use the end-
point of RFS as a surrogate for OS, if RFS reliably predicts OS ben-
eﬁt, to assess the impact of new agents upon disease outcome
over shorter intervals. The ACCENT stage II–III colon cancer data-
base, which includes data from 20,898 patients from 18 random-
ized trials treated with adjuvant 5FU/LV or observation alone has
been critical for our understanding of the relationship between
DFS and OS. Sargent et al.154,155 found a strong correlation between
2- and 3-year DFS and 5-year OS, especially in stage III disease. In
addition, the DFS beneﬁt of adjuvant chemotherapy vs. observation
was signiﬁcant in the ﬁrst 2 years (with trends in years 3 and 4),
and the recurrence rate in the adjuvant treatment group never ex-
ceeded that of the observation group, supporting the hypothesis
that cure and not just delay in recurrence had been achieved.156
Using multiple hypothetical data sets from ACCENT157 and actual
data from six newer adjuvant studies158 where median survival
after recurrence has approximately doubled (from 12 to 20–
24 months), it was clear that stronger correlations exist between
2- and 3-year DFS and OS at >6 years as compared with 5 years.
However, the results of the NSABP C-07 trial of stage II and III colon
cancer patients should also be considered in this context. Three-
year DFS rates were improved with FLOX vs. 5FU/LV,45 but at a
median of 8-years’ follow up, although the DFS beneﬁt was main-
tained with FLOX, there was no difference in OS between the two
groups.32 Subgroup analysis suggested that patient age may impact
on the effects of oxaliplatin, as the 8-year OS beneﬁt was signiﬁ-
cant in patients <70 years old. Overall, 2- and 3-year DFS can prob-
ably be taken as surrogate endpoints to predict OS in trials that
continue to follow colon cancer patients for 6 or more years, with
the caveat that factors such as patient age may affect outcomes;
this warrants further research. These data are speciﬁc to colon
cancer but the model may also apply to other tumors, although
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sidered.159 The magnitude of impact upon DFS must also be sufﬁ-
cient to translate to an impact upon OS.Predictive markers of adjuvant therapy success
Clinicopathologic features associated with response to speciﬁc
therapeutic interventions are referred to as ‘‘predictive’’ factors
(e.g., tumor characteristics, biomarkers, gene expression patterns).
The success of individualizing adjuvant treatment rests on the
availability of large tumor banks linked to high-quality, prospec-
tively collected data in large clinical trials, which can be used to
accelerate the validation of prognostic factors and novel
biomarkers. Such markers are now being investigated in the vari-
ous solid tumors to work towards individualized therapy; the
key markers discussed in this section are summarized in
Table 4.16,24,26,108,109,160–165
In NSCLC studies, beneﬁt appeared to differ by disease stage. In
the JBR.10 trial of cisplatin-based adjuvant therapy, subset analysis
showed that the primary beneﬁt appeared with stage II disease,
with signiﬁcant improvement in 5-year OS of 59% vs. 44% for
observation. Paradoxically, patients with tumors <4 cm had clini-
cally poorer outcomes compared with patients in the observation
arm (5-year OS 73% vs. 79%, respectively) whereas patients with
tumors >4 cm had a signiﬁcant improvement in 5-year OS with
adjuvant chemotherapy (79% vs. 59%). In the ANITA trial, subset
analysis suggested that patients with stage II and IIIA disease de-
rived the most beneﬁt from adjuvant treatment, gaining absolute
beneﬁts in 5-year OS of 13% and 16%, respectively.24 Other poten-
tial predictive markers are under investigation in NSCLC. The ongo-
ing TASTE trial is directing therapy based upon DNA repair and cell
proliferation pathways (baseline tumor ERCC1 levels and EGFR
mutations), and an ongoing CALGB study is assigning treatment
based upon a genetic signature called the lung Metagene model.160
In colon cancer, Ribic et al.161 found a lack of OS beneﬁt for adju-
vant 5FU/LV vs. observation in microsatellite instability-high (MSI-
H) patients, with a trend towards higher mortality (p = 0.10), in
data from 5 large randomized trials. Sargent et al. pooled data from
5 high-quality prospective RCTs and conﬁrmed that in patients
with stage II MSI-H tumors, there was a lack of beneﬁt with adju-
vant 5FU in terms of DFS (HR = 2.30; 95% CI 0.84–6.24; p = 0.09)
and 5-year OS (HR = 2.95; 95% CI 1.02–8.54; p = 0.04) vs. observa-
tion.162 ECOG 5202 has recently completed enrollment of stage II
patients using MSI-H status as well as 18q loss of heterogeneity,
which is considered a poor prognostic factor, to categorize patients
into high vs. low risk and treat only high-risk patients with adju-
vant oxaliplatin-based therapy. Other strategies for identifyingTable 4
Predictive markers of response to therapy.
Tumor Predictive marker Sta
NSCLC Disease stage JBR
AN
Tumor ERCC1 levels Un
EGFR mutations Un
Genetic signature ‘lung Metagene model’ Un
Colon cancer Microsatellite instability Poo
Osteosarcoma, Ewing’s
sarcoma, soft tissue
sarcoma
Risk classiﬁcation based on speciﬁc histologic
subtypes, tumor grade, location and patient
characteristics
Molecular signatures Un
Melanoma Disease stage Gre
Ulceration of primary tumor Gre
Breast cancer Oncotype DX™ 21-gene assay Pre
wh
gre
Mammaprint 70-gene assay Prehigh-risk colon cancer patients include multi-gene expression pro-
ﬁles to predict recurrence and response to adjuvant therapy. Kerr
et al.166 presented a large, prospectively designed validation study
using patients enrolled in the QUASAR trial. Seven prognostic
genes signiﬁcantly and monotonically predicted recurrence risk
as well as DFS and OS, and retained prognostic signiﬁcance
independent of T stage, nodes examined, lymphovascular invasion,
tumor grade, and MSI status. Unfortunately, six treatment–
beneﬁt genes were unable to predict a response to adjuvant
chemotherapy.
The utility of adjuvant therapy in sarcoma was revealed when
neoadjuvant chemotherapy was utilized to allow time for surgical
planning and construction of osseous and joint prostheses, and also
seemed to provide beneﬁt related to treating micrometastatic dis-
ease. Use of neoadjuvant chemotherapy also allows the evaluation
of histologic response to this initial treatment,167 thereby inform-
ing the selection of adjuvant chemotherapy. Appropriate patient
selection is at the heart of obtaining beneﬁt from adjuvant chemo-
therapy of sarcomas. Current parameters involve risk classiﬁcation
on the basis of speciﬁc histologic subtypes (e.g., synovial sarcoma,
rhabdomyosarcoma, osteosarcoma, Ewing’s), tumor grade (low,
intermediate, or high), location (extremity vs. non-extremity),
and patient characteristics (performance status, comorbidities,
personal values). The advent of therapies that are more effective
for certain subtypes (trabectedin for liposarcoma and leiomyosar-
coma, or gemcitabine-docetaxel for uterine sarcomas) will inform
better treatment decisions on the basis of histology, but for the
majority of sarcomas, other selection strategies are direly needed.
Several molecular signatures have been developed in small studies
that could allow a better patient selection algorithm and improve
the risk/beneﬁt ratio; however, those signatures still await pro-
spective validation.163,164,168 The EORTC is planning an adjuvant
study with trabectedin (ET-743) in patients with high-grade STS
with a molecular signature based on DNA repair proteins. Efforts
guided by a biological understanding of the mechanisms underly-
ing tumor recurrence and resistance to chemotherapy are likely to
yield the most beneﬁt.
In the analysis of outcomes across trials of high-dose IFNa2b in
melanoma, there has been no consistent stage-related impact of
therapy, and the beneﬁts have been observed for patients with
bulky nodal disease (AJCC IIIB) from the earliest pivotal trial
E1684 onward. Subanalysis of data from the 18991 PEG-IFN-a2b
study suggests that micrometastatic disease (N1 or AJCC IIIA) is a
predictor of adjuvant therapy beneﬁt in stage III melanoma. PEG-
IFN-a2b signiﬁcantly improved RFS and DMFS vs. observation in
the subset of patients with microscopic nodal involvement, but
no beneﬁt was found in the subset of patients with macroscopic
nodal involvement (N2, AJCC IIIB). The signiﬁcant difference intus
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ater beneﬁt from chemotherapy vs. tamoxifen16
dicts which patients may beneﬁt most from adjuvant chemotherapy
36 J.M. Kirkwood et al. / Cancer Treatment Reviews 39 (2013) 27–43RFS in the N1 group persisted at the 7.6 year follow-up (HR = 0.82;
99% CI 0.61–1.10; p = 0.08).109 These ﬁndings point to potential dif-
ferences in tumor biology in early vs. advanced disease. In a post
hoc meta-analysis of data from EORTC studies 18991 and 18952
(intermediate dosage IFNa-2b for 1 or 2 years vs. observation in
stage IIB–III patients), RFS, DMFS and OS beneﬁts were greater in
the subgroup of patients with primary tumor ulceration (n = 849)
vs. non-ulcerated (n = 1336) patients. In addition, the greatest
reductions in risk were seen in patients with primary tumor ulcer-
ation and microscopic nodal N1 disease, with an HR = 0.69
(p = 0.003) for RFS, HR = 0.59 (p < 0.0001) for DMFS, and
HR = 0.58 (p < 0.0001) for OS.169 These data suggest that both tu-
mor burden (stage) and biology (primary tumor ulceration) may
predict the efﬁcacy of therapy with intermediate doses of adjuvant
IFN-a2b or PEG-IFN-a2b therapy. In melanoma, a clear path to the
efﬁcient evaluation of therapeutic efﬁcacy, and the mechanism of
action has been reported using neoadjuvant trial designs. Neoadju-
vant studies of IFN-a2b12 have demonstrated levels of antitumor
activity that are several-fold higher than observed in inoperable
advanced melanoma and revealed the immunological rather than
anti-angiogenic or antitumor basis of action for this agent. More
recent neoadjuvant evaluation of ipilimumab has shown a role in
modulating myeloid-derived suppressor cells in the blood of mel-
anoma patients, and further neoadjuvant studies of new, molecu-
larly targeted agents and combinations of targeted and
immunological, as well as doublets of immunological therapy,
are likely to provide a more facile and informative path to optimi-
zation of these therapeutic agents and combinations for adjuvant
therapy.
In breast cancer, several multiparameter gene expression assays
are now routinely used in clinical practice. Oncotype DX™ (Geno-
mic Health Inc., Redwood City, CA) is a 21-gene assay that has been
shown to predict response to tamoxifen and chemotherapy. An
expert ASCO panel concluded that ‘‘. . .the Oncotype DX assay can
be used to predict the risk of recurrence in patients treated with
tamoxifen. . .(and) may be used to identify patients who are pre-
dicted to obtain the most therapeutic beneﬁt from adjuvant
tamoxifen and may not require adjuvant chemotherapy. In addi-
tion, patients with high recurrence scores appear to achieve rela-
tively more beneﬁt from adjuvant chemotherapy (speciﬁcally
cyclophosphamide, methotrexate, and 5FU) than from tamoxi-
fen.’’16 Since that publication in 2007, other studies have shown
that the assay provides prognostic information for AI-treated post-
menopausal patients,170 and also predicts beneﬁt from anthracy-
cline-based chemotherapy for postmenopausal women with
axillary node-positive disease.171 Other assays, such as the 70-gene
Mammaprint assay, have also been shown to provide useful prog-
nostic information.172 Several randomized clinical trials are now in
progress to further deﬁne the clinical utility of these assays in clin-
ical practice. TAILORx173 (NCT00310180) and RxPONDER
(NCT01272037) are investigating Oncotype DX and MINDACT174
(NCT00433589) is comparing genomic proﬁling using the Mamma-
print assay, with clinical assessment to determine the need for che-
motherapy in women with node-negative breast cancer. In
addition, CYP2D6 polymorphisms that result in diminished enzyme
activity and biotransformation of tamoxifen to its active metabo-
lite (endoxifen) have been associated with a higher risk of recur-
rence in tamoxifen-treated patients;175–177 however, routine
testing for CYP2D6 polymorphisms remains controversial.178Future directions for adjuvant therapy
As new, ‘‘targeted’’ agents with activity in advanced disease are
identiﬁed, the next logical step will be to study them in the
adjuvant setting. As our understanding of tumor biology and therelevant progression pathways for solid tumors increases, new
treatment modalities or combinations may also be of beneﬁt in
the adjuvant setting. These new approaches, coupled with the
use of the predictive markers discussed above to better select
patients who are more likely to respond to such therapy, offer
the prospect of more rapidly developing and more precisely under-
standing the mechanism of action for new adjuvant therapies,
toward optimization and ultimate individualization of adjuvant
therapy.
In NSCLC, ongoing randomized phase III adjuvant trials are
investigating chemotherapy with and without the anti-angiogenic
agent bevacizumab (ECOG E1505) and the role of erlotinib in
patients with overexpression of the EGFR gene (RADIANT). As in
other solid tumors where cancer-germline antigens are strongly
expressed, the potential relevance of immunotherapy is currently
under evaluation. The cancer-germline vaccine MAGE-A3 is being
tested in NSCLC tumors expressing the tumor-speciﬁc MAGE-A3-
antigen (MAGRIT trial).179 MAGE-A3 may be present in up to 50%
of early NSCLCs.
In resected colon cancer, the focus of clinical investigation is
currently on improving adjuvant therapy combinations, inclusion
of biologic agents, and improved risk stratiﬁcation to better predict
the potential beneﬁt of adjuvant therapy and aid the interpretation
of clinical trial results, particularly in stage II disease. The newest
AJCC staging manual180 acknowledges a more reﬁned prognostica-
tion for colon cancer including subdivision of T4 tumors as well as
nodal status. These subcategories can vary in SEER-observed 5-
year OS by as much as 10–15% and may help better risk-stratify pa-
tients for adjuvant chemotherapy. Currently, international efforts
are focused on investigating the utility of 6 versus 12 cycles of FOL-
FOX in stage III colon cancer in an effort to balance the intent of
cure with that of leaving patients with chronic, adverse cumulative
effects from oxaliplatin (e.g., chronic neuropathy). In addition, CAL-
GB 80702 will be randomizing patients to 3 years of celecoxib
(COX-2 inhibitor) vs. placebo in order to explore the practical util-
ity of these agents in improving DFS.
Management of sarcomas is multidisciplinary because of the
multitude of potential sites of incidence requiring expertise in
orthopedic, surgical, medical, and radiation oncology. Evidence
suggests that patients treated at high-volume centers with special-
ized expertise in sarcoma management have improved out-
comes.181 The Children’s Oncology Group is conducting a study
(COG-AOST0331) in which patients with poor histologic response
to standard therapy are randomized to receive alternating cycles
of IE with the standard cisplatin/doxorubicin/methotrexate regi-
men. The expression of multiple cancer-germline antigens in sar-
coma poses an opportunity for adjuvant immunotherapy, but to
date this has not been fully embraced. In the COG-AOST0331trial,
patients showing a favorable histologic response to chemotherapy
are randomized to observation or maintenance immunotherapy
with PEG-IFN-a2b for 1 year after surgery and chemotherapy, in
follow-up to a Swedish study that suggested antitumor activity
of IFN in osteosarcoma.182
CTLA-4-blocking antibodies (ipilimumab, tremelimumab) have
shown promise as monotherapy of metastatic melanoma,183,184
although as discussed above, this may not translate to the adjuvant
setting. RCTs are currently testing the beneﬁt of therapy with high-
dose (10 mg/kg) ipilimumab vs. placebo (EORTC 18071) and vs.
standard high-dose IFN-a2b (US Intergroup E1609) as adjuvant
therapy for high-risk stage III or stage IIIB/IV resectable melanoma;
no data are expected from either of these studies for several years.
Anti-CTLA-4 therapy has novel immunologic mechanisms of
action, disrupting the immune checkpoint molecule CTLA-4, a
key regulator of T cell activity that plays an important role in main-
taining tolerance.185 Its toxicities, including skin, liver, endocrine
and GI immune-related toxicity, have posed new, potentially
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quire rigorous follow-up and anticipatory management of patients.
The identiﬁcation of activating mutations in the BRAF gene in >50%
of patients with cutaneous melanoma, and the recent dramatic
successes of second-generation small molecule BRAF inhibitors in
advanced melanoma,186,187 has also prompted consideration of
their adjuvant application, alone or with MEK inhibitors that have
been shown to mitigate some of the toxicities of the BRAF inhibi-
tors.188,189 Vaccines are under evaluation as adjuvant immunother-
apy for melanoma following promising EORTC phase I–II studies
testing the MAGE-A3 vaccine given with a potent new immuno-
modulator (CpG), which has shown results superior to prior immu-
nomodulators. As in NSCLC, application of vaccine immunotherapy
with MAGE-A3 requires expression of the antigen in the tumor.
Expression of MAGE-A3 was found in 66% of patients with mela-
noma, so appears not to be a limiting factor. In melanoma, the eval-
uation of a predictive gene signature that may be associated with
greater MAGE-A3 vaccine antitumor efﬁcacy is also being evalu-
ated.190,191 Combinations of new agents and established immuno-
modulators are the likely future of adjuvant therapy for melanoma.
In breast cancer, several randomized clinical trials are now in
progress that will further deﬁne the clinical utility of geneTable 5
Clinical beneﬁt of adjuvant therapy vs. observation or placebo (control) across tumor type
Tumor type Ha
Dis
NSCLC
Cisplatin-based CT (ALPI)
Median follow-up 64.5 months21 0.8
Cisplatin-based CT (IALT; n = 1867)22
Median follow-up 56 months22 0.8
Median follow-up 7.5 years25 0.8
Cisplatin + vinorelbine (JBR.10)23 0.6
Median follow-up 9.3 years26
Cisplatin + vinorelbine (ANITA)24
Cisplatin-based CT meta-analysis (LACE; n = 4584)192 0.8
Colon
5FU/LV (IMPACT)30 0.6
Stage II onlya 0.8
Stage III onlya 0.5
5FU/LV (IMPACT) stage B2 onlyb,49 0.8
5FU/LV (QUASAR) stage 233 0.7
5FU/LV (ACCENT)156 0.6
Soft tissue sarcoma
Meta-analysis of doxorubicin-based regimens (14 trials)95 0.7
Meta-analysis of doxorubicin-based regimens (18 trials)96
Doxorubicin alone
Doxorubicin + ifosfamide
Melanoma
IFN-a meta-analysis (all doses)107 0.8
IFN-a individual patient data meta-analysis (all doses)106 0.8
High-dose IFN-a (pooled data 4 studies)107 0.7
IFN-a105 0.8
PEG-IFN-a2b (EORTC 18991; n = 1256)108 0.8
7.6 year follow up109 0.8
Breast
Single-agent CT meta-analysis116 0.8
PolyCT meta-analysis116 0.7
Anthracycline-based CT 10-year meta-analysis117 0.7
CMF-based CT 10-year meta-analysis117 0.7
Tamoxifen 1–2 years meta-analysis (ER-positive patients)116 0.7
Tamoxifen 5-years meta-analysis (ER-positive patients)116 0.5
CMF, cyclophosphamide/methotrexate/ﬂuorouracil; CT, chemotherapy; ER, estrogen
pegylated interferon-a2b.
a Unadjusted data.
b Adjusted for age and grade.
c Annual event ratio (treatment vs. control) and standard error.
d Event rate ratio and 95% conﬁdence interval (treatment vs. control).expression assays in clinical practice as discussed previously,
including the TAILORx,173 MINDACT,174 and RxPONDER trials.Discussion
Postoperative adjuvant therapy is now a standard consideration
inmany resectable solid tumors, and signiﬁcantly reduces the risk of
recurrence vs. observation. In an attempt to compare magnitude
of efﬁcacy across different tumor types we have compared
studies assessing adjuvant therapy vs. observation alone
(Table 521–26,30,33,49,95,96,105–109,116,117,156,192 and Table
621–25,30,49,95,101,104,108,116,117,156,192,193). In tumors for which adju-
vant therapy has now evolved, these rates are likely to be conserva-
tive estimates of beneﬁt. HRs for DFS improvement range from 0.59
(SE 0.03) for 5-year tamoxifen in breast cancer to 0.89 (95% CI 0.76–
1.03; not signiﬁcant) for cisplatin-based chemotherapy in NSCLC,
although themajority fall between 0.75–0.9 and are statistically sig-
niﬁcant, suggesting relatively consistent effects upon DFS (Table 5).
Thebeneﬁts uponOS are less pronounced and there have been fewer
signiﬁcant improvements at intervals ofmore than1–2 years. None-
theless, OS beneﬁts are observed, with HRs of 0.56 (0.36–0.85;s: data from meta-analyses, pooled studies and large, controlled trials.
zard ratio (95% conﬁdence interval) vs. control
ease-free survival Overall survival
9 (0.76–1.03); p = 0.128 0.96 (0.81–1.13); p = 0.589
3 (0.74–0.94); p < 0.003 0.86 (0.76–0.98); p < 0.03
8 (0.78–0.98); p = 0.02 0.91 (0.81–1.02); p = 0.10
0; p < 0.001 0.69; p = 0.04
0.78 (0.61–0.99); p = 0.04
0.80 (0.66–0.96); p = 0.017
4 (0.78–0.91); p < 0.001 0.89 (0.82–0.96); p = 0.005
7 (0.56–0.80); p < 0.0001 0.77 (0.62–0.96); p = 0.018
4 (0.62–1.12) 0.91 (0.63–1.34)
5 (0.44–0.70) 0.70 (0.53–0.92)
8 (0.72–1.07) 0.86 (0.68–1.07)
8 (0.67–0.91) p = 0.001 0.82 (0.70–0.95) p = 0.008
1 (estimated years 1–2) 0.74 (estimated over 8 years)
5 (0.64–0.87); p = 0.0001 0.89 (0.76–1.03); p = 0.12
0.84 (0.68–1.03); p = 0.09
0.56 (0.36–0.85); p = 0.01
3 (0.77–0.90); p = 0.000003 0.93 (0.85–1.02); p = NS
7 (0.81–0.93); p = 0.00006 0.90 (0.84–0.97); p = 0.008
4 0.86 (0.74–1.00); p = 0.05
2 (0.77–0.87); p < 0.001 0.89 (0.83–0.96); p = 0.002
2 (0.71–0.96); p = 0.01 0.98 (0.82–1.16); p = 0.78
7 (0.76–1.00); p = 0.05 0.96 (0.82–1.11); p = 0.57
6c (0.04); 2p = 0.001 0.96c (0.05); 2p > 0.1
7c (0.02); 2p < 0.00001 0.83c (0.02); 2p < 0.00001
3d (0.68–0.79); 2p < 0.00001 0.84d (0.78–0.91); 2p < 0.00001
0d (0.63–0.77); 2p < 0.00001 0.84d (0.76–0.93); 2p = 0.0004
4c (0.02) 0.82c (0.03)
9c (0.03) 0.66c (0.04)
receptor; 5FU/LV, 5-ﬂuorouracil + leucovorin; IFN-a, interferon-a; PEG-IFN-a2b,
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0.04) for breast cancer, and 0.77 (0.62–0.96; p = 0.018) for colorectal
cancer, suggesting that a magnitude of RFS impact in the order of
0.70–0.80 may be required to achieve a meaningful impact upon
OS. A modest impact upon RFS (HR = 0.87; 0.76–1.00; p = 0.05 for
PEG-IFN-a2b in melanoma) has shown no corresponding impact
upon OS (0.96; 0.82–1.11; p = 0.57), although analysis of patient
subsets indicate that the effects may be conﬁned to those with
low tumor burden (micrometastatic N1 disease). Differences in efﬁ-
cacy outcomes according to disease stage have also been suggested
by clinical trial data inNSCLC.Morewidespreaduse of the predictive
markers that are now becoming available for each of the tumor
types will allow better selection of the patients who will beneﬁt
from adjuvant therapy; it is therefore reasonable to expect to see
greater improvements in both DFS and OS with adjuvant therapy
in the future.
As expected for different tumor types, the 5-year and 10-year
DFS and OS data are variable (Table 6). In some tumors the magni-
tude of improvement in DFS and OS is concordant (e.g., NSCLC),
while for others the impact upon DFS exceeds that upon OS (e.g.,
melanoma). Regardless of the relationship between DFS and OS,
DFS is an important endpoint for the assessment of therapeutic
beneﬁt, given its earlier maturity, impact upon quality-of-life,
and the debilitating consequences of recurrent disease.154
The adjuvant therapies employed in solid tumors reﬂect our
current knowledge of the molecular pathogenesis of each disease,
and the associated immunopathology of some solid tumors such
as melanoma. Emerging targeted therapies demonstrate greater
speciﬁcity than conventional chemotherapy but are believed toTable 6
Comparisons of 5- and 10-year disease-free survival and overall survival data across diffe
Tumor type Disease-free survival: differ
therapy vs. no therapy, %
5-year
Lung
Cisplatin-based CT meta-analysis (LACE; n = 4584)192 5.8
Median follow-up 7.5 years25 Absolute gain 4.3
Cisplatin-based CT (IALT, n = 1867)22 5 (p < 0.003)
Cisplatin + vinorelbine23 12 (p = 0.08)
Cisplatin + vinorelbine (ANITA)24
Cisplatin-based CT (ALPI)21 Absolute increase 4 (95% CI
Colon
5FU/LV (IMPACT)30 9a
5FU/LV (IMPACT) Stage B2 only49 3 (p = NS)
5FU-based CT (ACCENT)156
Stage II
Stage III
5FU-based CT (elderly)193 11 (p < 0.001)
Soft tissue sarcoma
Doxorubicin-based meta-analysis (14 trials)95
Melanoma
IFN-a2b E1684 trial (n = 287)104 11 (p = 0.0023)
IFN-a2b E1690 trial (n = 642)101 HDI arm 9 (p2 = 0.03)
PEG-IFN-a2b (EORTC 18991; n = 1256)108
All patients 7c (p = 0.01)
Stage N1 only 13c (p = 0.016)
Breast
PolyCT meta-analysis116
<50 years 12.5
50–69 years 6.0
Anthracycline-based CT meta-analysis117 8.5
Standard CMF-based CT meta-analysis117 9.9
Tamoxifen 5 years meta-analysis (ER positive)116 11.4
CT, chemotherapy; ER, estrogen receptor; 5FU/LV, 5-ﬂuorouracil + leucovorin; IFN-a2b,
a 3-year data. Signiﬁcance testing not reported.
b 8-year data.
c 4-year data.be unlikely to achieve durable beneﬁts in the management of most
solid tumors as single agents, given the multiple pathways identi-
ﬁed in the progression of each solid tumor and the reactivation of
the key driver pathways through multiple changes in the tumor,
associated with targeted inhibitors (e.g., of BRAFV600E in mela-
noma) to date. Their use is likely to be in combination with existing
adjuvant therapies. The role of immunity has been established in
the progression of some solid tumors and not in others. The role
of immunomodulation has been pursued perhaps most aggres-
sively in melanoma, where the importance of immune response
is recognized regarding disease prognosis and outcome, and where
adjuvant chemotherapy was ineffective and molecular therapies
did not exist until recently. In breast cancer, the complex algorithm
used for determining the most appropriate adjuvant therapy
reﬂects the broader understanding of its heterogeneity, and the
efﬁcacy of chemo-, hormonal-, and molecularly targeted therapy
tailored according to tumor histopathology, hormone receptor
status, and HER2 status.
The balance between the therapeutic outcome, acute toxicity,
and long-term side effects is an important consideration for adju-
vant therapy and should be determined on an individual patient
basis. Patient age and their likely tolerance of treatment may also
need to be factored in. The majority of adjuvant therapies are asso-
ciated with toxicity that may limit or delay their administration;
however, the beneﬁts are generally agreed to outweigh the poten-
tial risks, given unequivocal improvements in DFS and/or OS. The
tolerability of more intensive chemotherapy regimens may fall
with increasing intensity of therapy. In breast cancer, the expected
effects of hormone therapy (e.g., hot ﬂushes, menstrual cyclerent tumor types vs. no adjuvant therapy.
ence with adjuvant Overall survival: difference with adjuvant therapy vs.
no therapy, %
10-year 5-year 10-year
5.4
Absolute gain 3.9
5 (p < 0.03)
15 (p = 0.03)
8.6
–1, 10) Absolute increase 1 (95% CI –4, 7)
5a
2 (p = NS)
7.2b (p < 0.0001)
5.4b (p = 0.026)
10.3b (p < 0.0001)
7 (p < 0.001)
10
(95% CI 5, 15)
4
(95% CI 1, 9)
9 (p = 0.0237)
–3 (p = NS)
1c (p = NS)
4c (p = NS)
12.4 4.7 7.9
4.7 2.6 2.9
8 5.1 5.0
10.2 2.7 4.7
13.6 3.6 7.9
interferon-a2b; PEG-IFN-a2b, pegylated interferon-a2b.
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although they affect patient compliance, and potentially compro-
mise efﬁcacy. Adherence to tamoxifen after surgery for breast
cancer is modest, with <50% of women continuing therapy for
the prescribed 5 years in one UK study.194 Long-term toxicity of
adjuvant therapies are also an issue, such as musculoskeletal and
cardiovascular problems associated with AIs in breast cancer and
possible late, non-cancer-related mortality in NSCLC. In melanoma,
the greater impact upon RFS than OS in multiple trials of IFN-a has
raised the question of morbidity associated with treatment that
does not improve survival.
In summary, adjuvant therapy given for operable disease earlier
in the course of progression for multiple solid tumors has demon-
strated clear beneﬁts in terms of reduced risk of recurrence and
improved OS. OS beneﬁts have been smaller in general than the
RFS beneﬁts for a number of solid tumors. To optimize the beneﬁts
and reﬁne the application of adjuvant therapy the focus is now
shifting towards more precise staging and risk stratiﬁcation for
each disease, since the beneﬁts and the risk–beneﬁt ratio may dif-
fer according to patient subset (e.g., macro- vs. micrometastatic
nodal disease). Further optimization of adjuvant therapy will also
likely emerge from mechanistically tailoring therapy to target both
tumor cell drivers of progression, and the host immune deﬁcits
that permit tumor evasion of immunity. The disparity between
the beneﬁts observed in the differing stage groupings of disease
may not only be related to the burden of disease and overall prog-
nosis but also to different disease biology in localized and nodal
disease, or between different biological processes such as angio-
genesis associated with certain primary disease prognostic groups
(e.g., ulcerated and non-ulcerated melanoma). The identiﬁcation of
more precise prognostic indicators and factors that will predict
therapeutic beneﬁt (e.g., hormone receptor and HER2/neu expres-
sion in breast cancer, antigen expression for vaccine therapies,
and gene expression proﬁling for multiple solid tumors) may
better guide the application of each therapy. These advances may
allow individualization of therapy and further improvement of
the risk–beneﬁt ratio. As research advances with the expansion
of our knowledge of the molecular and cellular basis of progression
in these tumors, adjuvant therapy is likely to be reﬁned further,
with greater improvements in long-term survival and the potential
for cure of solid tumors using multimodal therapies informed by
the biology of the underlying disease.Conﬂict of interest statement
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